Audicus
Audicus operates an online platform offering hearing aids directly to consumers, disrupting the traditional hearing aid market by providing affordable, high-quality hearing devices without the overhead of audiologist offices. The company's direct-to-consumer model eliminates middlemen and reduces costs significantly compared to traditional hearing aid dispensers, making hearing healthcare more accessible to the…
Funding snapshot
About
Audicus operates an online platform offering hearing aids directly to consumers, disrupting the traditional hearing aid market by providing affordable, high-quality hearing devices without the overhead of audiologist offices. The company's direct-to-consumer model eliminates middlemen and reduces costs significantly compared to traditional hearing aid dispensers, making hearing healthcare more accessible to the millions of Americans with hearing loss. Audicus offers a range of hearing aid models with modern features including rechargeability, Bluetooth connectivity, and smartphone app control, catering to varying levels of hearing loss and user preferences. The platform provides online hearing tests and personalized programming, allowing customers to purchase and configure their hearing aids from home. By combining telehealth consultations with direct shipping, Audicus enables customers to receive professional hearing care without in-person clinic visits. Founded in 2011 and headquartered in Hoboken, New Jersey, Audicus has raised $8.5M in Series A funding from investors including Middleland Capital, Fisher Capital Investments, Continuity Capital, Howzat Partners, Econa, and TIA Ventures.
Business model
Wearable Technology > Health and Wellness Devices > Ear Care > Hearing Impairment > Internet First Brands,
Assistive Tech > Assistive Hardware > Hearing > Hearing aids,
ENT Disorders > Medical Devices > Therapeutic Devices > Ear > Hearing Impairment
Team background
Company Wise > Bain, McKinsey,
College Wise > Massachusetts Institute of Technology
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.